PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$864M
This Quarter Return
+20.97%
1 Year Return
+33.7%
3 Year Return
+258.24%
5 Year Return
+878.92%
10 Year Return
–
AUM
$815M
AUM Growth
+$815M
(+15%)
Cap. Flow
+$60M
Cap. Flow
% of AUM
7.37%
Top 10 Holdings %
Top 10 Hldgs %
31.52%
Holding
117
New
28
Increased
37
Reduced
32
Closed
17
Top Buys
| 1 |
Eli Lilly
LLY
|
$25M |
| 2 |
Cooper Companies
COO
|
$21.3M |
| 3 |
Fortrea Holdings
FTRE
|
$17.2M |
| 4 |
Schrodinger
SDGR
|
$16.1M |
| 5 |
Oscar Health
OSCR
|
$12.4M |
Top Sells
| 1 |
Amgen
AMGN
|
$17.7M |
| 2 |
Boston Scientific
BSX
|
$15.6M |
| 3 |
Keros Therapeutics
KROS
|
$12.1M |
| 4 |
Mettler-Toledo International
MTD
|
$9.1M |
| 5 |
Humana
HUM
|
$8.28M |
Sector Composition
| 1 | Healthcare | 99.46% |
| 2 | Industrials | 0.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Arvinas
ARVN
$568M
| $5.16M | 0.63% | 124,979 -42,022 | -25% | -$1.73M |
|
52
MoonLake Immunotherapeutics
MLTX
$3.54B
| $5.08M | 0.62% | 101,071 +19,062 | +23% | +$957K |
|
53
Arcus Biosciences
RCUS
$1.13B
| $4.91M | 0.6% | 259,920 +12,256 | +5% | +$231K |
|
|
PHLT
54
Performant Healthcare, Inc. Common Stock
PHLT
$603M
| $4.88M | 0.6% | 1,659,100 +78,235 | +5% | +$230K |
|
|
ITCI
55
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $4.84M | 0.59% | 69,892 -116,380 | -62% | -$8.05M |
|
56
Charles River Laboratories
CRL
$8.04B
| $4.8M | 0.59% | +17,697 | New | +$4.8M |
|
57
NewAmsterdam Pharma
NAMS
$2.71B
| $4.74M | 0.58% | 200,311 -100,439 | -33% | -$2.38M |
|
58
Crinetics Pharmaceuticals
CRNX
$2.92B
| $4.73M | 0.58% | 101,119 -19,533 | -16% | -$914K |
|
59
Alphatec Holdings
ATEC
$2.35B
| $4.64M | 0.57% | +336,688 | New | +$4.64M |
|
60
Standard BioTools
LAB
$481M
| $4.53M | 0.56% | 1,670,401 +1,066,781 | +177% | +$2.89M |
|
61
Centene
CNC
$14.3B
| $4.38M | 0.54% | +55,794 | New | +$4.38M |
|
|
AUGX
62
DELISTED
Augmedix, Inc. Common Stock
AUGX
| $4.36M | 0.54% | 1,066,109 +50,295 | +5% | +$206K |
|
|
AKYA
63
DELISTED
Akoya BioSciences
AKYA
| $4.3M | 0.53% | 917,442 +242,655 | +36% | +$1.14M |
|
64
Quanterix
QTRX
$211M
| $4.15M | 0.51% | 176,112 +29,746 | +20% | +$701K |
|
65
Lyra Therapeutics
LYRA
$11.5M
| $3.99M | 0.49% | 642,245 -112,640 | -15% | -$701K |
|
66
Nurix Therapeutics
NRIX
$714M
| $3.68M | 0.45% | +250,000 | New | +$3.68M |
|
67
Merus
MRUS
$4.98B
| $3.61M | 0.44% | 80,123 -77,694 | -49% | -$3.5M |
|
68
Nuvalent
NUVL
$5.52B
| $3.59M | 0.44% | 47,808 -12,059 | -20% | -$906K |
|
69
Dynavax Technologies
DVAX
$1.19B
| $3.31M | 0.41% | 266,510 +12,563 | +5% | +$156K |
|
70
Elanco Animal Health
ELAN
$9.12B
| $3.28M | 0.4% | +201,181 | New | +$3.28M |
|
71
Esperion Therapeutics
ESPR
$448M
| $3.06M | 0.38% | 1,142,897 -282,307 | -20% | -$757K |
|
72
Cullinan Oncology
CGEM
$445M
| $3.04M | 0.37% | 178,396 -351,481 | -66% | -$5.99M |
|
73
IDEAYA Biosciences
IDYA
$2.15B
| $2.91M | 0.36% | 66,332 -63,933 | -49% | -$2.81M |
|
74
UroGen Pharma
URGN
$900M
| $2.76M | 0.34% | 184,184 +8,684 | +5% | +$130K |
|
75
Nkarta
NKTX
$151M
| $2.72M | 0.33% | +252,028 | New | +$2.72M |
|